D

Diffusion Pharmaceuticals Inc
NASDAQ:CRVO

Watchlist Manager
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
Watchlist
Price: 12.54 USD 0.08% Market Closed
Market Cap: 103.5m USD
Have any thoughts about
Diffusion Pharmaceuticals Inc?
Write Note

EV/EBIT
Enterprise Value to EBIT

-8.9
Current
-6.6
Median
3.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-8.9
=
Enterprise Value
95.7m USD
/
EBIT
-10.8m USD
All Countries
Close
EBIT Growth
US
D
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
Average EV/EBIT: 24.7
Negative Multiple: -8.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -211 198.6 N/A
US
Abbvie Inc
NYSE:ABBV
26.2
88%
US
Amgen Inc
NASDAQ:AMGN
35.7
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.6
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A
AU
CSL Ltd
ASX:CSL
26.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
20.1
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -75.1 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-6.6
2-Years Forward
EV/EBIT
-2.9
3-Years Forward
EV/EBIT
-2

See Also

Discover More